Stocks In News: HPCO, CCJ, MRNA
1:53 pm Wednesday, October 12th, 2022
Hempacco (NASDAQ:HPCO) stock is taking off on Wednesday after announcing results for its first half of 2022. According to a press release, Hempacco brought in revenue of $2.8 million for the six months ending June 30, 2022. The company notes that this is a massive 486% year-over-year increase in revenue. Hempacco notes that there are a few reasons why its revenue saw such a dramatic jump in the first half of the year. That includes its plans to rapidly expand operations while also doing so in an efficient way.
Cameco (NYSE:CCJ) stock is slipping on Wednesday after the company announced its intent to acquire Westinghouse Electric Company. Cameco isn’t buying Westinghouse Electric on its own. The company is forming a strategic partnership with Brookfield Renewable Partners (NYSE:BEP) that will see them splitting ownership of the nuclear power company. That deal will see Cameco hold a 49% stake in Westinghouse Electric. The remaining 51% will belong to Brookfield Renewable. This has them sharing the $4.5 billion equity cost with Cameco covering $2.2 billion and Brookfield Renewable handling the other $2.3 billion.
Could this be a collaboration that saves lives? That’s the billion-dollar question today as Moderna (NASDAQ:MRNA) is reportedly working with Merck (NYSE:MRK) to develop an mRNA-based cancer vaccine. The purpose is to advance a personalized or tailored cancer treatment. We may be witnessing a signal moment in the history of vaccine development. At the very least, we’re seeing a good day for MRNA stock investors as the shares are quickly moving higher.
